Micafungin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Invasive candidiasis 100 mg once daily for at least 14 days, may increase to 200 mg once daily if necessary. Oesophageal candidiasis 150 mg once daily for at least 1 wk after resolution of clinical signs and symptoms. Prophylaxis of Candida infection in haematopoietic stem cell transplantation recipients 50 mg once daily for at least 1 wk after neutrophil recovery.
Dosage Details
Intravenous
Invasive candidiasis
Adult: 100 mg once daily by infusion over 1 hr for at least 14 days, may increase to 200 mg once daily if clinical response is inadequate. Continue treatment for at least 1 wk after obtaining 2 sequential –ve blood cultures and after resolution of clinical signs and symptoms.
Child: <16 yr ≤40 kg: 2 mg/kg once daily by infusion over 1 hr for at least 14 days; may increase to 4 mg/kg once daily if clinical response is inadequate. Continue treatment for at least 1 wk after obtaining 2 sequential –ve blood cultures and after resolution of clinical signs and symptoms; >40 kg: Same as adult dose.

Intravenous
Oesophageal candidiasis
Adult: 150 mg once daily by infusion over 1 hr for at least 1 wk after resolution of clinical signs and symptoms.
Child: ≥16 yr ≤40kg: 3 mg/kg once daily by infusion over 1 hr; >40 kg: Same as adult dose.

Intravenous
Prophylaxis of candida infection in haematopoietic stem cell transplantation recipients
Adult: 50 mg once daily by infusion over 1 hr for at least 1 wk after neutrophil recovery.
Child: <16 yr ≤40 kg: 1 mg/kg once daily by infusion over 1 hr; >40 kg: Same as adult dose.
Reconstitution
Reconstitute vials labelled as containing micafungin 50 mg or 100 mg w/ 5 mL of NaCl 0.9% or dextrose 5% inj to provide a soln containing approx 10 mg/mL or 20 mg/mL, respectively. Prepare the soln for IV infusion by adding the contents of the appropriate number of reconstituted vials to 100 mL of NaCl 0.9% or dextrose 5% inj.
Incompatibility
Y-site: Incompatible w/ diltiazem, amiodarone, albumin, cisatracurium, epinephrine, insulin (regular), dobutamine, labetalol, vecuronium, midazolam, meperidine, morphine, mycophenolate, nesiritide, nicardipine, ondansetron, octreotide, phenytoin, rocuronium, telavancin.
Contraindications
Hypersensitivity to micafungin or other echinocandins.
Special Precautions
Patient w/ pre-existing risk of malignancy. Severe hepatic impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Nausea, vomiting, diarrhoea, pyrexia, thrombocytopenia, headache, histamine-mediated symptoms (e.g. pruritus, rash, swelling, vasodilation), renal dysfunction or acute renal failure, inj site reactions (e.g. phlebitis, thrombophlebitis). Rarely, haemolysis (e.g. acute intravascular haemolysis, haemolytic anaemia).
Potentially Fatal: Severe hepatic dysfunction, hepatitis or hepatic failure; anaphylaxis and anaphylactoid reactions, including shock.
IV/Parenteral: C
MonitoringParameters
Monitor liver function.
Drug Interactions
May increase exposure of amphotericin B desoxycholate, sirolimus, nifedipine, itraconazole.
Action
Description: Micafungin prevents the synthesis of 1,3-β-D-glucan, an essential fungal cell wall component, by non-competitively inhibiting 1,3-β-D-glucan synthase. Decreased glucan content results in osmotic instability and cellular lysis.
Pharmacokinetics:
Distribution: Rapidly distributed into body tissues. Volume of distribution: 0.28-0.5 L/kg. Plasma protein binding: >99%, mainly albumin.
Metabolism: Metabolised by arylsulfatase to its catechol form and further metabolised by COMT to the methoxy form; also undergoes some hydroxylation by CYP3A isoenzyme.
Excretion: Mainly via faeces (71%); urine (12%). Mean half-life: 14-17.2 hr.
Chemical Structure

Chemical Structure Image
Micafungin

Source: National Center for Biotechnology Information. PubChem Database. Micafungin, CID=477468, https://pubchem.ncbi.nlm.nih.gov/compound/Micafungin (accessed on Jan. 22, 2020)

Storage
Store at 25°C.
MIMS Class
ATC Classification
J02AX05 - micafungin ; Belongs to the class of other systemic antimycotics.
References
Anon. Micafungin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/01/2016.

Buckingham R (ed). Micafungin Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/01/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Micafungin Sodium. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 06/01/2016.

Mycamine Injection, Powder, Lyophilized, for Solution (Astellas Pharma US, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/01/2016.

Disclaimer: This information is independently developed by MIMS based on Micafungin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in